506P - Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m)
| Autor: | Garcia-Carbonero, R., Van Cutsem, E., Ciardiello, F., Ychou, M., Seitz, J.-F., Hofheinz, R.D., Arriaga, Y., Verma, U., Grothey, A., Miriyala, A., Kalmus, J., Kappeler, C., Falcone, A., Zaniboni, A. |
|---|---|
| Zdroj: | In Annals of Oncology 1 October 2016 27 Supplement 6:vi167-vi167 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|